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Background: Autosomal Emery-Dreifuss muscular dystrophy is caused by mutations in the lamin A/C gene (LMNA)
encoding A-type nuclear lamins, intermediate filament proteins of the nuclear envelope. Classically, the disease manifests as
scapulo-humeroperoneal muscle wasting and weakness, early joint contractures and dilated cardiomyopathy with
conduction block; however, move variable skeletal muscle involvement can be present. Previously, we demonstrated
increased activity of extracellular signal-regulated kinase (ERK) 1/2 in hearts of LmnaH222P/H222P mice, a model of autosomal
Emery-Dreifuss muscular dystrophy, and that blocking its activation improved cardiac function. We therefore examined the
role of ERK1/2 activity in skeletal muscle pathology.
Methods: Sections of skeletal muscle from LmnaH222P/H222P mice were stained with hematoxylin and eosin and histological
analysis performed using light microscopy. ERK1/2 activity was assessed in mouse tissue and cultured cells by
immunoblotting and real-time polymerase chain reaction to measure expression of downstream target genes.
LmnaH222P/H222P mice were treated with selumetinib, which blocks mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase 1/2 that activates ERK1/2, from 16 to 20 weeks of age to assess the effects of treatment
on muscle histology, ERK1/2 activity and limb grip strength.
Results: We detected enhanced activation of ERK1/2 in skeletal muscle of LmnaH222P/H222P mice. Treatment with
selumetinib ameliorated skeletal muscle histopathology and reduced serum creatine phosphokinase and aspartate
aminotransferase activities. Selumetinib treatment also improved muscle function as assessed by in vivo grip
strength testing.
Conclusions: Our results show that ERK1/2 plays a role in the development of skeletal muscle pathology in
LmnaH222/H222P mice. They further provide the first evidence that a small molecule drug may be beneficial for
skeletal muscle in autosomal Emery-Dreifuss muscular dystrophy.
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Emery-Dreifuss muscular dystrophy (EDMD) is classically
characterized clinically by a triad of: (1) slowly progressive
muscle weakness and wasting in a scapulo-humeroperoneal
distribution; (2) early contractures of the elbows, ankles,
and posterior neck; and (3) dilated cardiomyopathy with
conduction defects [1,2]. Contractures are usually the first
clinical sign of the disease occurring in the first decade of
life. During the second decade of life, the slowly progressive
muscle weakness and wasting typically begin. At the end of
the second decade, most patients develop evidence of car-
diomyopathy [3-5].
EDMD can be inherited in a X-linked or autosomal fash-
ion. X-linked EDMD is caused by mutations in EMD en-
coding emerin [6]. Emerin is an integral protein of the
inner nuclear membrane [7,8]. The majority of autosomal
dominant and less frequent recessive cases are caused by
mutations in LMNA [9,10]. LMNA encodes two major
somatic cell polypeptides, lamin A and lamin C, which are
components of the nuclear lamina, a meshwork of inter-
mediate filaments on the inner aspect of the inner nuclear
membrane [11-14]. While the classical EDMD phenotype
was first attributed to EMD and LMNA mutations, it is
now apparent that the same mutations in these genes can
cause dilated cardiomyopathy with more variable skeletal
muscle involvement [6,9,15-21]. Intriguingly, LMNA muta-
tions (different than those leading to myopathy) can also
cause partial lipodystrophy, peripheral neuropathy, or accel-
erated aging disorders such as Hutchinson-Gilford progeria
syndrome [22].
Despite the relatively recent advances in understanding
the genetics of EDMD and related myopathies, the patho-
genic mechanisms leading to striated muscle damage are
only poorly understood. One useful small animal model to
study pathogenesis and evaluate potential therapeutic inter-
ventions in autosomal EDMD is the LmnaH222P/H222P
mouse [23]. Starting at approximately 16 weeks, male
LmnaH222P/H222P develop progressive dystrophic pathology
in several skeletal muscle groups. Later, they have progres-
sive accumulation of connective tissue in skeletal muscle.
LmnaH222P/H222P mice also develop dilated cardiomyopathy
with conduction system abnormalities and significant car-
diac fibrosis.
We have previously shown that LmnaH222P/H222P mice
have increased activity of the mitogen-activated protein
kinase extracellular signal-regulated kinase (ERK) 1/2 in
cardiac muscle [24]. This increased ERK1/2 activity occurs
prior to the onset of overt tissue pathology, suggesting that
it plays a primary pathogenic role. Treatment of
LmnaH222P/H222P mice with drugs that inhibit mitogen-
activated protein kinase/extracellular signal-regulated kin-
ase kinase (MEK) 1/2, the kinase that activates ERK1/2,
leads to improved left ventricular ejection fraction [25,26],
decreased cardiac fibrosis [26,27] and prolonged survival[27]. While these results strongly suggest that abnormal
ERK1/2 activation contributes to the development of car-
diomyopathy in LmnaH222P/H222P mice, its pathogenic role
in affected skeletal muscles is unknown.
Based on our findings in heart, we hypothesize that abnor-
mal activation of ERK1/2 is similarly involved in the patho-
genesis of skeletal muscular dystrophy in the LmnaH222P/H222P
mouse model of EDMD. In the present study, we demon-
strate increased activation of ERK1/2 in affected skeletal
muscle these mice. We further show that treatment with
the MEK1/2 inhibitor selumetinib ameliorates pathological
changes and improves function. These results suggest that
MEK1/2 inhibitors may be beneficial in treating both car-
diac and skeletal muscle disease in patients with EDMD.
Methods
Mice
LmnaH222P/H222P mice were bred and genotyped as pre-
viously described [23]. Mice were fed chow and housed
in a disease-free barrier facility with 12 h/12 h light/dark
cycles. The Institutional Animal Care and Use Commit-
tee at Columbia University Medical Center approved the
use of animals and the study protocols.
Drug treatment protocol and harvesting of muscle
samples
Selumetinib (Selleck Chemicals) was dissolved in dimethyl
sulfoxide (DMSO) (Sigma) at a concentration of 0.5 mg/
mL to allow for intraperitoneal injections in mice. The pla-
cebo control consisted of the same volume of DMSO.
Selumetinib was delivered at a dose of 1 mg/kg daily by in-
traperitoneal injection using a 27 5/8-gauge syringe starting
when mice were 16 weeks of age and continuing until 20
weeks of age. At the end of the study, mice were sacrificed
and hindlimb and diaphragm muscles dissected. Part of
each dissected muscle was frozen in liquid nitrogen and
stored at -80°C for biochemical analysis. The remaining
muscle was rapidly frozen in isopentane pre-chilled by li-
quid nitrogen for cryostat sectioning.
Histology
Frozen pieces of quadriceps femoris, diaphragm, and tibialis
anterior were mounted in Tissue-Tek (Fisher Scientific) and
10 μm sections cut on a cryostat. Sections were stained with
hematoxylin and eosin for histological analysis. Representa-
tive sections were photographed using a Microphot SA
(Nikon) light microscope attached to a Spot RT Slide cam-
era (Diagnostic Instruments). Images were processed using
Adobe Photoshop CS (Adobe Systems).
Osmotic shock of C2C12 cells stably expression wild-type
and H222P lamin A
Generation of stable C2C12 cells expressing wild-type
and H222P lamin A has been described previously [28].
Figure 1 Skeletal muscle pathology in LmnaH222P/H222P mice. (A) Representative micrographs of hematoxylin and eosin-stained sections of
quadriceps, diaphragm, and tibialis anterior muscles from 20-week-old male LmnaH222P/H222P mice (Lmna H222P). Similar sections from wild-type mice
(Lmna WT) are shown for comparison. Scale bar = 50 mm. Arrows indicate internalized nuclei. To the right of each pair of micrographs, quantitative
analyses of muscle fiber diameter (Feret’s diameter) are shown for wild-type (circles, sold line) and LmnaH222P/H222P mice (squares, dashed line). Values are
means ± SEM for n = 3 mice per group; **P <0.005, ***P <0.0005. (B) Bar graphs showing percentages of fibers in specified muscle groups with internalized
nuclei. Values shown are means ± SEM for between 500 and 1,000 nuclei analyzed in tissue samples 3 per group; *P <0.05, **P <0.005, n.s. not significant.
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subcultured at approximately 60% to 70% confluence in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum (Invitrogen). To assess the im-
pact of osmotic shock on the activation of ERK1/2, cells
were treated with D-sorbitol (600 mM) for 1 h and pro-
teins were harvested in RIPA extraction buffer (Cell Sig-
naling Technology) as previously described [24].
Quantitative real-time reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA was extracted using the RNeasy isolation
kit (Qiagen). Total RNA was used to synthesize cDNA
using SuperScript First-strand Synthesis System
(Invitrogen) according to the manufacturer’s instruc-
tions. For each replicate in each experiment, RNA from
tissue samples of different animals was used. Primers
were designed corresponding to mouse RNA se-
quences using Primer3 [29]. Real-time quantitative RT-
PCR reactions contained HotStart-IT SYBR green
qPCR Master Mix (Affymetrix), 200 nM of each primerand 0.2 μL of template in a reaction volume of 25 μL.
Amplification was carried out using the ABI 7300
Real-time PCR System (Applied Biosystems). Relative
levels of mRNA expression were calculated using the ΔΔCT
method [30] and individual expression values were normal-
ized by comparison to GapdhmRNA.
Protein extraction and immunoblotting
Skeletal muscle was homogenized in RIPA extraction
buffer (Cell Signaling Technology) as previously de-
scribed [24]. Extracted proteins were separated by SDS-
polyacrylamide gel electrophoresis, transferred to nitro-
cellulose membranes, and blotted with primary anti-
bodies against ERK1/2 and phosphorylated ERK1/2 (Cell
Signaling Technology). Secondary antibodies were horse-
radish peroxidate-conjugated (GE Healthcare). Recognized
proteins were visualized by enhanced chemiluminescence
(GE Healthcare). To quantify results, the immunoblots
were scanned and band densities calculated using ImageJ64
(Applied Imaging). Signals obtained for phosphorylated
ERK1/2 were normalized to those for total ERK1/2.
Figure 2 Increased ERK1/2 activity in skeletal muscle of LmnaH222P/H222P mice. (A) Immunoblots showing phosphorylated ERK1/2 (p-ERK1/2)
and total ERK1/2 in protein extracts from quadriceps, diaphragm, and tibialis anterior muscles of 20-week-old male wild-type (Lmna WT) and
LmnaH222P/H222P (Lmna H222P) mice. Each lane contains protein extracts from a different mouse. The bar graph shows means ± SEM values of
pERK1/2 normalized to total ERK1/2 from scanned band densities of five immunoblots from n = 5 different mice per group. **P <0.005, ***P
<0.0005. (B) Differential expression of 11 selected genes in the ERK1/2 signaling pathway analyzed using real-time quantitative RT-PCR in
quadriceps, diaphragm, and tibialis anterior muscles of 20-week-old male wild-type and LmnaH222P/H222P mice. White bars show relative RNA
expression levels in skeletal muscles from wild-type mice Lmna+/+ mice and black bars in skeletal muscles from LmnaH222P/H222P mice. Values are
means ± SEM for n = 5 mice per group; the real-time quantitative RT-PCR was performed in triplicate on each different RNA sample. *P <0.05, **P
<0.005, ***P <0.0005, n.s. not significant.
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Serum was separated from mouse blood and stored at -80°C
for 3 to 9 months until analyzed. Creatine phosphokinase
(CPK) and aspartate aminotransferase (AST) activities were
measured using an Analyst III Analyzer (Hemagen Diagnos-
tics) in the Comparative Pathology Laboratory at Columbia
University Medical Center. CPK and AST activities have
been shown to be stable in rodent serum stored for up to
360 days at -70°C [31].
Limb grip strength measurements
LmnaH222P/H222P mice treated with DMSO or selumetinib
were subjected to limb grip strength testing using a hori-
zontally positioned grip strength meter (Bioseb). Micewere lowered by the tail towards the grid on the apparatus.
Upon grasping the grid with their limbs, mice were pulled
backward in the horizontal plane. The procedure was re-
peated consecutively three times and the peak tension of
the three pulls was recorded as the grip strength value.
Each animal was subjected to a total of two serial trials of
three pulls each with 20 s of rest in between.
Statistics
Values for real-time quantitative RT-PCR, scanned im-
munoblots, internalized nuclei, serum CPK and AST ac-
tivities, and grip strength were compared using an
unpaired Student t-tests. Values for Feret’s diameter
were compared using two-way ANOVA. Statistical
Figure 3 Cultured myoblasts expressing H222P lamin A have
greater ERK1/2 activity after osmotic shock than those
expressing wild-type lamin A. One hour after osmotic shock with
D-sorbitol, protein extracts from C2C12 cells stably expressing flag-
tagged wild-type lamin A (Lmna WT) and flag-tagged H222P lamin
A (Lmna H222P) were analyzed by immunoblotting. Blots were
probed with antibodies against phosphorylated ERK1/2 (pERK1/2),
total ERK1/2 (ERK1/2) and Flag. The immunoblot shown is
representative of three separately performed experiments.
Figure 4 Increased ERK1/2 activity in skeletal muscle of
LmnaH222P/H222P mice at 16 weeks of age. Immunoblot showing
phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2 in protein
extracts from quadriceps of 16-week-old male wild-type (Lmna WT)
and LmnaH222P/H222P (Lmna H222P) mice. Each lane contains protein
extracts from a different mouse. The bar graph shows means ± SEM
values of pERK1/2 normalized to total ERK1/2 from scanned band
densities of three immunoblots from n = 3 different mice per group.
*P <0.05.
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Results and discussion
Dystrophic skeletal muscle pathology in LmnaH222P/H222P
mice
Arimura et al. [23] previously reported progressive dys-
trophic changes in skeletal muscle starting at 16 weeks male
LmnaH222P/H222P mice. Their non-quantitative histopatho-
logical analysis included descriptions of a wide variation in
fiber size, an increased number of atrophic, hypertrophic,
and lobulated fibers, some regenerative fibers and a men-
tion that some fibers had internalized nuclei. We therefore
carefully quantified myofiber diameters and internalized
nuclei in histological sections of quadriceps, diaphragm,
and tibialis anterior muscle of male wild-type and
LmnaH222P/H222P mice at 20 weeks of age. Compared to
wild-type mice, quadriceps and tibialis anterior from the
LmnaH222P/H222P mice exhibited a wider variation in fiber
size (Figure 1A). In quadriceps, there was a clear shift to-
wards smaller fiber diameters, consistent with the pres-
ence of greater numbers of atrophic and regenerative
fibers. Both of these muscle groups also had an increased
percentage of fibers with internal nuclei, which is observed
during regeneration (Figure 1A,B). At this age, however,
diaphragm did not show significant differences between
LmnaH222P/H222P and wild-type mice (Figure 1A,B).Abnormal ERK1/2 signaling in skeletal muscle of
LmnaH222P/H222P mice
Hearts of LmnaH222P/H222P mice and human subjects
with autosomal EDMD have increased activity of ERK1/
2, which likely plays a role in pathogenesis of cardiomy-
opathy [24-27]. We hypothesized that a similar increased
activation of this signaling pathway occurs in skeletal
muscle. We therefore examined ERK1/2 activity in skel-
etal muscle from 20-week-old male LmnaH222P/H222P
mice. Immunoblotting with antibody against phosphory-
lated (activated) ERK1/2 demonstrated a two-fold in-
crease in activity in quadriceps, diaphragm, and tibialis
anterior of LmnaH222P/H222P mice compared to wild type
mice (Figure 2A). We then used quantitative real-time
PCR to measure expression of downstream ERK1/2 tar-
get genes, several of which are members of the ETS fam-
ily of transcription factors that are phosphorylated by
ERK1/2 and positively autoregulate their transcriptional
activity [24,32,33]. Of 11 targets genes assessed, we
detected significantly increased expression of mRNAs
Figure 5 Selumetinib inhibits ERK1/2 phosphorylation in
skeletal muscles from LmnaH222P/H222P mice. Representative
immunoblots using antibodies against phosphorylated ERK1/2
(pERK1/2) and total ERK1/2 (ERK1/2) to probe proteins extracts from
quadriceps, diaphragm, and tibialis anterior from 20-week-old male
LmnaH222P/H222P mice treated with selumetinib or DMSO for 4 weeks.
The immunoblot shown is representative of three separately
performed experiments.
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alis anterior of LmnaH222P/H222P mice compared to wild-
type controls (Figure 2B). Among these, Mef-2, Elk1, Atf2,
Atf4, and Nfatc-4 showed significantly increased expres-
sion in the three skeletal muscles examined. These data
demonstrate that ERK1/2 is hyperactivated in the skeletal
muscles of LmnaH222P/H222P mice. Increased ERK1/2 acti-
vation in diaphragm at an age before there is any detect-
able histological abnormalities is consistent with its
increased activity in heart prior to the onset of detectable
pathological signs of cardiomyopathy [24]. This suggests
that increased ERK1/2 signaling is involved in the patho-
genesis of dystrophic skeletal muscle pathology.Stress-induced activation of ERK1/2 in cultured myoblasts
stably expressing H222P lamin A
We have previously shown that transient transfection of
C2C12 mouse myoblasts with cDNA encoding H222P
prelamin A or other variants associated with striated
muscle disease have increased ERK1/2 activity compared
to those transfected with a cDNA encoding wild-type
prelamin A [24]. However, stably transfected C2C12 cells
expressing H222P lamin A do not have increased ERK1/
2 activity at baseline but do after glucose depravation or
treatment with 5-aminoimidazole-4-carboxyamide ribo-
nucleoside [28]. This led us to hypothesize that physio-
logical stress, such as that associated with manipulations
necessary for transient transfection or induced by altered
energy metabolism, is necessary to increase ERK1/2 ac-
tivity in myoblasts expressing lamin A variants. We fur-
ther tested this hypothesis by subjecting the same cells
stably expressing lamin A H222P that do not have base-
line elevation in ERK1/2 [28] to osmotic shock. One
hour after an osmotic shock with 600 mM D-sorbitol,
cells expressing flag-tagged H222P lamin A had a greater
activity of ERK1/2 compared to those expressing flag-
tagged wild-type lamin A (Figure 3). This result provided
additional support for a model in which alterations in
the nuclear lamina associated with striated muscle dis-
ease lead to abnormalities in the activities of cellular
stress-responsive signaling pathways [24,34,35]. The re-
quirement of a stress to hyperactivate ERK1/2 in cells
expressing the H222P lamin A may also at least in part
explain why striated muscle, a tissue repeatedly under
mechanical strain, is preferentially affected by LMNA
mutations generating certain A-type lamin variants.
Blocking ERK1/2 activity with selumetinib has beneficial
effects on skeletal muscle in LmnaH222P/H222P mice
Given the enhanced ERK1/2 activity in skeletal muscle
of LmnaH222P/H222P mice that develop muscular dys-
trophy, we hypothesized that it may contribute to path-
ology. To test this hypothesis, we set up experiments to
determine if inhibiting ERK1/2 signaling would prevent
the progression of muscular dystrophy. At 16 weeks of
age, ERK1/2 activity was elevated in quadriceps muscle
of LmnaH222P/H222P mice compared to wild-type mice, as
assessed by immunoblotting with antibody against phos-
phorylated kinase (Figure 4).
We administered the MEK1/2 inhibitor selumetinib
to male LmnaH222P/H222P mice by giving daily intraper-
itoneal injections (1 mg/kg) starting at 16 weeks of age.
After 4 weeks of treatment, the mice had reduced
phosphorylated ERK1/2 in quadriceps, tibialis anterior,
and diaphragm compared to placebo-treated mice.
This demonstrated that systemically administered
selumetinib inhibited ERK1/2 signaling in skeletal
muscle (Figure 5).
Figure 6 (See legend on next page.)
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Figure 6 Selumetinib from 16 to 20 weeks of age improves skeletal muscle pathology and function in LmnaH222P/H222P mice.
(A) Expression of Myh3 in LmnaH222P/H222P mice measured using real-time quantitative RT-PCR. White bars show relative RNA expression levels in
skeletal muscles of DMSO-treated (white bars) and selumetinib-treated (black bars) mice. Values are means ± SEM for n = 5 mice per group; the
real time RT-PCR was performed in triplicate with the different RNA sample; *P <0.05. (B) Representative micrographs of hematoxylin and eosin-
stained sections of quadriceps from 20-week-old male LmnaH222P/H222P mice (Lmna H222P) treated for 4 weeks with DMSO or selumetinib. Scale
bar = 50 mm. Arrows indicate internalized nuclei. To the right of the micrographs, quantitative analyses of muscle fiber diameter (Feret’s
diameter) are shown for mice treated with DMSO (circles, solid line) and selumetinib (squares, sold line). Values are means ± SEM for n = 3 mice
per group; **P <0.005, ***P <0.0005. (C) Serum CPK activities in LmnaH222P/H222P mice at 16 weeks (16 W) and 20 weeks (20 W) of age that were
treated with DMSO (white bars) or selumetinib (black bars). Values are means ± SEM for n = 7 DMSO-treated mice and n = 15 selumetinib-
treated mice; **P <0.005, n.s. not significant, #P <0.05. (D) Grip strength (force) in Newtons (N) in LmnaH222P/H222P mice at 20 weeks of age that
were treated with DMSO (circles) (n=6) or selumetinib (squares) (n=8). Each circle and square represents a measurement from an individual
mouse; the longer horizontal bar are means and the shorter horizontal bars ± SEM; **P <0.05.
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was significantly reduced expression of embryonic my-
osin heavy chain (Myh3) mRNA in quadriceps, dia-
phragm, and tibialis anterior of LmnaH222P/H222P mice
(Figure 6A). This represented a partial reversal of embry-
onic myosin expression that typically occurs in dystrophic
muscle [36,37]. While quadriceps from DMSO-treated
mice had 0.52% fibers (4/772 from three mice) with inter-
nalized nuclei (Figure 6A, arrows), there were none
detected in 571 fibers from three mice in the selumetinib-
treated mice (and 1/604 fibers from three wild-type mice as
shown in Figure 1B). DMSO treatment did not impact
myofiber diameter compared to untreated LmnaH222P/H222P
mice; however, mice treated with selumetinib had a greater
myofiber diameter in quadriceps compared to those treated
with DMSO (Figure 6B). Between 16 and 20 weeks of age,
there was a significant increase in serum CPK activity in
LmnaH222P/H222P mice treated with DMSO; however, CPK
activity did not significantly increase in the mice that re-
ceived selumetinib and at 20 weeks it was significantly
lower than in those that received DMSO (Figure 6C).
Mean serum AST activity was also significantly lower in
the selumetinib-treated mice compared to the placebo-
treated mice at 20 weeks of age (data not shown). To de-
termine if selumetinib improved skeletal muscle function
in LmnaH222P/H222P mice, we evaluated limb grip strength.
At 20 weeks of age, mean grip strength was significantly
greater in selumetinib-treated LmnaH222P/H222P mice than
in DMSO-treated mice (Figure 6D). Hence, selumetinib
improved skeletal muscle dystrophic pathology and im-
proved function in LmnaH222P/H222P mice.
Conclusions
We have shown increased activity of ERK1/2 in skeletal
muscle of the LmnaH222P/H222P mouse model of auto-
somal EDMD and that blocking its activity ameliorates
pathology. These results are in accordance with a grow-
ing body of research providing evidence that alterations
in various cellular signaling pathways, including ERK1/2,
are involved in the pathogenesis of muscular dystrophy
[38]. In addition to autosomal EDMD, ERK1/2 has beenimplicated as contributing to skeletal or cardiac muscle
pathology in mdx [39-41], γ-sarcoglycan-deficient [42,43],
and Lama2Dy-w [44] mice, respective small animal models
of Duchenne, limb girdle type 2C, and a form of congenital
muscular dystrophy. ERK1/2 activity is also abnormally in-
creased in hearts of mice with emerin deficiency, which is
the genetic alteration in X-linked EDMD [45].
Blocking increased ERK1/2 signaling activity with
selumetinib had beneficial effects on skeletal muscle func-
tion in LmnaH222P/H222P mice. Previously, we obtained
similar results with respect to the cardiomyopathy that oc-
curs in these mice [24-27]. In a human clinical trial,
selumetinib has been reported to promote muscle gain in
patients with cholangiocarcinoma [46]. As oral selumetinib
and other orally bioavailable MEK1/2 inhibitors with en-
couraging safety profiles are currently in clinical develop-
ment for other indications [47,48], pilot trials in patients
with EDMD and possibly other muscular dystrophies
should be considered.
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